NOVEL BISPECIFIC CD3/CD19 POLYPEPTIDE COMPLEXES

    公开(公告)号:US20200283523A1

    公开(公告)日:2020-09-10

    申请号:US16648792

    申请日:2018-09-20

    摘要: A bispecific anti-CD3×CD19 polypeptide complex that contains a first antigen-binding moiety of the polypeptide complex and a second antigen-binding moiety, methods of producing the bispecific anti-CD3×CD19 polypeptide complex, methods of treating disease or disorder using the bispecific anti-CD3×CD19 polypeptide complex, polynucleotides encoding the bispecific anti-CD3×CD19 polypeptide complex, vectors and host cells containing said polynucleotides, and compositions and pharmaceutical compositions comprising the bispecific anti-CD3×CD19 polypeptide complex are provided.

    NOVEL ANTI-CD3EPSILON ANTIBODIES
    4.
    发明申请

    公开(公告)号:US20200299384A1

    公开(公告)日:2020-09-24

    申请号:US16649149

    申请日:2018-09-20

    发明人: Jing LI Qin MEI

    IPC分类号: C07K16/28 A61K47/68

    摘要: The present disclosure provides isolated monoclonal anti-CD3epsilon antibodies or antigen-binding fragments thereof comprising one or more heavy chain CDR sequences selected from the group consisting of: SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 47, and/or one or more kappa light chain CDR sequences selected from the group consisting of: SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the use thereof.

    NOVEL ANTI-CD3EPSILON ANTIBODIES
    5.
    发明公开

    公开(公告)号:US20230203159A1

    公开(公告)日:2023-06-29

    申请号:US17816731

    申请日:2022-08-02

    发明人: Jing LI Qin MEI

    IPC分类号: C07K16/28 C07K16/30

    摘要: The present disclosure provides isolated monoclonal anti-CD3epsilon antibodies or antigen-binding fragments thereof comprising one or more heavy chain CDR sequences selected from the group consisting of: SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 47, and/or one or more kappa light chain CDR sequences selected from the group consisting of: SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the use thereof.

    NOVEL BISPECIFIC CD3/CD20 POLYPEPTIDE COMPLEXES

    公开(公告)号:US20220162312A1

    公开(公告)日:2022-05-26

    申请号:US17425870

    申请日:2020-01-22

    摘要: The present disclosure provides a bispecific anti-CD3×CD20 polypeptide complex that contains a first antigen-binding moiety of the polypeptide complex and a second antigen-binding moiety, methods of producing the bispecific anti-CD3×CD20 polypeptide complex, methods of treating disease or disorder using the bispecific anti-CD3×CD20 polypeptide complex, polynucleotides encoding the bispecific anti-CD3×CD20 polypeptide complex, vectors and host cells containing said polynucleotides, and compositions and pharmaceutical compositions comprising the bispecific anti-CD3×CD20 polypeptide complex.